Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

3

Revenue 2017

Roche

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Roche's 2013 sales performance.

Roche

Roche to buy cancer data firm Flatiron for $1.9bn

Roche to buy cancer data firm Flatiron for $1.9bn

Roche to buy cancer data firm Flatiron for $1.9bn. Data provides a wealth of RWE opportunities. ... Roche Pharma chief executive Daniel O’Day “is a key ingredient to accelerate the development of, and access to, new cancer treatments”.

Merck/Pfizer’s cancer immunotherapy latecomer hits a snag

Merck/Pfizer’s cancer immunotherapy latecomer hits a snag jostling for market share with other entrants, namely Roche’s Tecentriq (atezolizumab) and AstraZeneca’s Imfinzi (durvalumab).

The good, the bad and the ugly

The good, the bad and the ugly Sanofi has overtaken Roche and Pfizer to reclaim its place at the top of the rankings. ... These two players will have a comfortable advantage over their nearest rival - Roche ($57bn).

Pfizer files third-gen ALK inhibitor for lung cancer

Pfizer files third-gen ALK inhibitor for lung cancer of competitive pressure from Roche’s fast-growing rival Alecensa (alectinib), a second-generation inhibitor that is well-tolerated and has the added benefit of penetrating the brain, which can help

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Finding the patient voice
How patients feel and speak about clinical trials...
Six Factors to Consider When Designing Advisory Boards
...
The good, the bad and the ugly
Tracking the pharmaceutical industry’s 2017 evolution and assessing how things may shape up in 2018 - it’s a trilogy of trends...

Infographics